James E. Flynn - 19 Dec 2022 Form 4 Insider Report for Oncorus, Inc.

Role
*Possible Member of 10% Group, 10%+ Owner
Signature
/s/ Jonathan Isler, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 Dec 2022
Net transactions value
-$37,628
Form type
4
Filing time
21 Dec 2022, 18:09:24 UTC
Previous filing
15 Dec 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCR Common Stock Sale $12,874 -44,394 -3.2% $0.2900* 1,351,374 19 Dec 2022 Through Deerfield Healthcare Innovations Fund, L.P. F1, F4, F5
transaction ONCR Common Stock Sale $12,874 -44,394 -3.2% $0.2900* 1,351,374 19 Dec 2022 Through Deerfield Private Design Fund III, L.P. F1, F4, F5
transaction ONCR Common Stock Sale $3,170 -10,930 -3.2% $0.2900* 332,725 19 Dec 2022 Through Deerfield Partners, L.P. F1, F4, F5
transaction ONCR Common Stock Sale $2,034 -6,562 -0.49% $0.3100* 1,344,812 20 Dec 2022 Through Deerfield Healthcare Innovations Fund, L.P. F2, F4, F5
transaction ONCR Common Stock Sale $2,034 -6,562 -0.49% $0.3100* 1,344,812 20 Dec 2022 Through Deerfield Private Design Fund III, L.P. F2, F4, F5
transaction ONCR Common Stock Sale $501 -1,616 -0.49% $0.3100* 331,109 20 Dec 2022 Through Deerfield Partners, L.P. F2, F4, F5
transaction ONCR Common Stock Sale $1,843 -6,144 -0.46% $0.3000* 1,338,668 21 Dec 2022 Through Deerfield Healthcare Innovations Fund, L.P. F3, F4, F5
transaction ONCR Common Stock Sale $1,843 -6,143 -0.46% $0.3000* 1,338,669 21 Dec 2022 Through Deerfield Private Design Fund III, L.P. F3, F4, F5
transaction ONCR Common Stock Sale $454 -1,513 -0.46% $0.3000* 329,596 21 Dec 2022 Through Deerfield Partners, L.P. F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.28 to $0.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1-3 of this Form 4.
F2 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.30 to $0.32, inclusive.
F3 The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.29 to $0.30, inclusive.
F4 This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
F5 In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.